316
Participants
Start Date
January 31, 2012
Primary Completion Date
April 30, 2013
Study Completion Date
April 30, 2013
metformin
1000 mg to 2000 mg per day
linagliptin
5 mg daily
metformin placebo
0 to 2 tablets daily
metformin placebo
4 tablets daily
1218.83.11002 Boehringer Ingelheim Investigational Site, Phoenix
1218.83.11036 Boehringer Ingelheim Investigational Site, Little Rock
1218.83.11011 Boehringer Ingelheim Investigational Site, Chino
1218.83.11001 Boehringer Ingelheim Investigational Site, Huntington Beach
1218.83.11019 Boehringer Ingelheim Investigational Site, Huntington Park
1218.83.11015 Boehringer Ingelheim Investigational Site, Lomita
1218.83.11023 Boehringer Ingelheim Investigational Site, Norwalk
1218.83.11014 Boehringer Ingelheim Investigational Site, Roseville
1218.83.11031 Boehringer Ingelheim Investigational Site, San Diego
1218.83.11022 Boehringer Ingelheim Investigational Site, Fort Lauderdale
1218.83.11025 Boehringer Ingelheim Investigational Site, Orlando
1218.83.11033 Boehringer Ingelheim Investigational Site, Sanford
1218.83.11029 Boehringer Ingelheim Investigational Site, Oakwood
1218.83.11026 Boehringer Ingelheim Investigational Site, Owensboro
1218.83.11008 Boehringer Ingelheim Investigational Site, Elkton
1218.83.11027 Boehringer Ingelheim Investigational Site, Freemont
1218.83.11005 Boehringer Ingelheim Investigational Site, Edison
1218.83.11013 Boehringer Ingelheim Investigational Site, Jacksonville
1218.83.11028 Boehringer Ingelheim Investigational Site, Salisbury
1218.83.11009 Boehringer Ingelheim Investigational Site, Shelby
1218.83.11003 Boehringer Ingelheim Investigational Site, Franklin
1218.83.11024 Boehringer Ingelheim Investigational Site, Gallipolis
1218.83.11018 Boehringer Ingelheim Investigational Site, Columbia
1218.83.11004 Boehringer Ingelheim Investigational Site, Bristol
1218.83.11017 Boehringer Ingelheim Investigational Site, Chattanooga
1218.83.11032 Boehringer Ingelheim Investigational Site, Grand Prairie
1218.83.11030 Boehringer Ingelheim Investigational Site, Houston
1218.83.11034 Boehringer Ingelheim Investigational Site, San Antonio
1218.83.11021 Boehringer Ingelheim Investigational Site, Tomball
1218.83.12011 Boehringer Ingelheim Investigational Site, Calgary
1218.83.12007 Boehringer Ingelheim Investigational Site, Edmonton
1218.83.12001 Boehringer Ingelheim Investigational Site, Red Deer
1218.83.12002 Boehringer Ingelheim Investigational Site, Paradise
1218.83.12009 Boehringer Ingelheim Investigational Site, St. John's
1218.83.12010 Boehringer Ingelheim Investigational Site, Greater Sudbury
1218.83.12005 Boehringer Ingelheim Investigational Site, Kitchener
1218.83.12006 Boehringer Ingelheim Investigational Site, London
1218.83.12003 Boehringer Ingelheim Investigational Site, Smiths Falls
1218.83.12012 Boehringer Ingelheim Investigational Site, Winnipeg
1218.83.91003 Boehringer Ingelheim Investigational Site, Bangalore
1218.83.91005 Boehringer Ingelheim Investigational Site, Chennai
1218.83.91001 Boehringer Ingelheim Investigational Site, Mumbai
1218.83.97004 Boehringer Ingelheim Investigational Site, Haifa
1218.83.97005 Boehringer Ingelheim Investigational Site, Haifa
1218.83.97007 Boehringer Ingelheim Investigational Site, Holon
1218.83.60001 Boehringer Ingelheim Investigational Site, Kelantan
1218.83.60002 Boehringer Ingelheim Investigational Site, Perak
1218.83.60003 Boehringer Ingelheim Investigational Site, Selangor, Malaysia
1218.83.52004 Boehringer Ingelheim Investigational Site, Cuautla
1218.83.52001 Boehringer Ingelheim Investigational Site, Guadalajara
1218.83.52002 Boehringer Ingelheim Investigational Site, Guadalajara
1218.83.52005 Boehringer Ingelheim Investigational Site, Mérida
1218.83.52003 Boehringer Ingelheim Investigational Site, Tampico
1218.83.63001 Boehringer Ingelheim Investigational Site, Cebu
1218.83.63007 Boehringer Ingelheim Investigational Site, Cebu City
1218.83.63003 Boehringer Ingelheim Investigational Site, Iloilo City
1218.83.63008 Boehringer Ingelheim Investigational Site, Iloilo City
1218.83.63002 Boehringer Ingelheim Investigational Site, Marikina City
1218.83.63006 Boehringer Ingelheim Investigational Site, Marikina City
1218.83.63004 Boehringer Ingelheim Investigational Site, Quezon
1218.83.11037 Boehringer Ingelheim Investigational Site, San Juan
1218.83.07001 Boehringer Ingelheim Investigational Site, Kazan'
1218.83.07002 Boehringer Ingelheim Investigational Site, Petrozavodsk
1218.83.07003 Boehringer Ingelheim Investigational Site, Saint Petersburg
1218.83.07007 Boehringer Ingelheim Investigational Site, Saint Petersburg
1218.83.07004 Boehringer Ingelheim Investigational Site, Samara
1218.83.07006 Boehringer Ingelheim Investigational Site, Smolensk
1218.83.07005 Boehringer Ingelheim Investigational Site, Yaroslavl
1218.83.94004 Boehringer Ingelheim Investigational Site, Dehiwala
1218.83.94002 Boehringer Ingelheim Investigational Site, Galle, Sri Lanka
1218.83.94003 Boehringer Ingelheim Investigational Site, Kandy
1218.83.94001 Boehringer Ingelheim Investigational Site, Ragama
1218.83.66002 Boehringer Ingelheim Investigational Site, Bangkok
1218.83.66003 Boehringer Ingelheim Investigational Site, Bangkok
1218.83.66001 Boehringer Ingelheim Investigational Site, Muang, Khonkaen
1218.83.38007 Boehringer Ingelheim Investigational Site, Dnipro
1218.83.38001 Boehringer Ingelheim Investigational Site, Ivano-Frankivsk
1218.83.38006 Boehringer Ingelheim Investigational Site, Kharkiv
1218.83.38004 Boehringer Ingelheim Investigational Site, Odesa
1218.83.38008 Boehringer Ingelheim Investigational Site, Vinnitsa
1218.83.38003 Boehringer Ingelheim Investigational Site, Vinnytsia
1218.83.38005 Boehringer Ingelheim Investigational Site, Vinnytsia
Lead Sponsor
Eli Lilly and Company
INDUSTRY
Boehringer Ingelheim
INDUSTRY